A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL) Meeting Abstract
| Authors: | Eradat, H. A.; Robak, T.; Delgado, J.; Schuh, A.; Pristupa, A. S.; Omyla-Staszewska, J.; Barrlentos, J. C.; Farber, C. M.; Macdonald, D.; Jacob, A.; Sharman, J. P.; Loscertales, J.; Brown, J. R.; Colffier, B.; Ghia, P.; Zelenetz, A. D.; Evans, S.; Jahn, T. M.; Hallek, M. J.; Hillmen, P. |
| Abstract Title: | A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202191 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.tps7127 |
| Notes: | Meeting Abstract: TPS7127 -- Source: Wos |
